Laila Tabatabai, MD
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1477788214
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $144,183 of the $206,942 with a category attached, or 69.7%. 18 manufacturers reported payments, led by Amgen at 46.3% of the total. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 444 payments — averaging $466.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$96K
- Kyowa Kirin, Inc.$64K
- Radius Health, Inc.$45K
- Abbott$359
- Lilly USA, LLC$276
- AstraZeneca$224
- plus $640 from 12 others
Across 96 payments — averaging $5974.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kyowa Kirin, Inc.$330K
- Ultragenyx Pharmaceutical Inc.$243K
What the payments were for
- Consulting fees$26,32013%
- Speaking & faculty fees$144,18370%
- Travel & lodging$24,94712%
- Food & beverage$11,4936%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 198 | $95,763 |
| Kyowa Kirin, Inc. | 109 | $64,483 |
| Radius Health, Inc. | 79 | $45,196 |
| Abbott | 15 | $359 |
| Lilly USA, LLC | 13 | $276 |
| AstraZeneca | 3 | $224 |
| Xeris Pharmaceuticals, Inc. | 7 | $133 |
| AbbVie | 6 | $125 |
| Ascendis Pharma Endocrinology Inc | 1 | $124 |
| Novo Nordisk | 4 | $85 |
| IBSA Pharma Inc. | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Ascensia Diabetes Care US Inc. | 1 | $25 |
| Mannkind Corporation | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Alvogen Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$206,942 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 179 | $465,349 |
| CrysvitaBurosumab-Twza | 20 | $304,786 |
| ForteoTeriparatide | 21 | $95,157 |
| OzempicSemaglutide | 59 | $64,001 |
| MounjaroTirzepatide | 44 | $48,220 |
| Teriparatide | 24 | $44,348 |
| SynthroidLevothyroxine Sodium | 74 | $6,578 |
| Raloxifene Hcl | 60 | $2,943 |
| Levothyroxine Sodium | 154 | $1,899 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 16 | $1,586 |
| Risedronate Sodium | 22 | $1,519 |
| Liothyronine Sodium | 37 | $1,476 |
| Estradiol (Twice Weekly)Estradiol | 14 | $1,247 |
| Estradiol (Once Weekly)Estradiol | 17 | $789 |
| Alendronate Sodium | 77 | $661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Radius Health, Inc.Tymlos | $45,196 | $465,349179 claims |
| Kyowa Kirin, Inc.Crysvita | $64,483 | $304,78620 claims |
| Lilly USA, LLCForteo, Mounjaro | $276 | $143,37665 claims |
| Novo NordiskOzempic | $85 | $64,00159 claims |
| Alvogen IncTeriparatide | $12 | $44,34824 claims |
| AbbVieSynthroid | $125 | $6,57874 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Houston
- Rocio HarbisonHouston$989K
- Andres SplenserHouston$923K
- Daniel TungHouston$753K
- Damaris VegaHouston$565K
- Steven PetakHouston$452K
- Amin JamalHouston$217K
- Rakesh PatelHouston$187K
- Veena WatweHouston$157K
- Tiana ShiverHouston$136K
- Lance SloanLufkin$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.